|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Department of Dermatology, University of Graz,
Austria.
Classification of primary cutaneous lymphomas (PCLs) is the subject
of ongoing controversy. Based on a series of 556 patients, the
applicability of the European Organization for Research and Treatment
of Cancer (EORTC) classification for PCLs was assessed and compared to
the proposed World Health Organization (WHO) classification of
hematologic malignancies. The large majority of patients could be
properly classified according to the scheme proposed by the EORTC.
Comparison of estimated 5-year survival for specific diagnostic categories of PCLs demonstrated nearly complete concordance of the
present results with those of the EORTC study for most of the indolent
cutaneous T-cell lymphomas and cutaneous B-cell lymphomas, whereas
differences were found for mycosis fungoides-associated follicular
mucinosis and Sezary syndrome. A few patients with newly described
entities (CD8+ epidermotropic cytotoxic T-cell lymphoma,
primary cutaneous natural killer/T-cell lymphoma) could not be
classified according to the EORTC scheme. Comparison of the EORTC with
the WHO classification showed that the EORTC scheme allows a more
precise categorization of the patients, especially for cutaneous B-cell
lymphoma. In conclusion, the study confirmed that the EORTC
classification allows a better management of patients with PCL. Small
amendments to that classification should be carried out to account for
recently described entities and to unify some of the diagnostic categories.
(Blood. 2002;99:800-805) Primary cutaneous lymphomas (PCLs) represent
distinct clinical and histopathologic subtypes of extranodal T- and
B-cell lymphomas. Until recently, they have been classified only
according to classification schemes devised mainly for nodal
non-Hodgkin lymphomas such as the Kiel or the Revised European-American
Lymphoma (REAL) classifications.1,2 Recently, the European
Organization for Research and Treatment of Cancer (EORTC)-Cutaneous
Lymphoma Project Group proposed a new classification of PCLs based on a
combination of clinical, histologic, and immunophenotypic
criteria.3 This classification has the aim of allowing a
more uniform diagnosis and treatment of patients with PCLs. The EORTC
classification has been the subject of criticism and
debates,4,5 and some dermatopathologists and
hematopathologists have suggested that PCLs should be classified according to the scheme currently being developed by the World Health Organization (WHO).6 Beside lymphoid neoplasms the
proposed WHO classification includes myeloid, histiocytic, and mast
cell neoplasms.6
Prognostic categories in the EORTC classification are based on data
from 626 patients collected in the Dutch Registry for Cutaneous
Lymphoma. A subsequent study by Grange and colleagues tested the
clinical validity of the EORTC classification in 158 patients with PCLs
other than mycosis fungoides, Sezary syndrome, and lymphomatoid
papulosis.7 With the exception of these 2 studies,
prognostic analyses on patients with PCLs were performed only in small
groups of patients.8-10
The aim of our study was to evaluate the applicability of the EORTC
classification for patients with PCLs and to compare it to the proposed
WHO classification. In addition, we compared survival data observed in
our group of patients with those reported in the EORTC study.
Data from 556 patients collected in the files of the Department
of Dermatology of the University of Graz between 1960 and 1999 were
included in this study. Excluded from the study were 109 patients
without adequate follow-up data as well as 11 unclassifiable cases. Of
the 556 patients, 353 (63.5%) were men and 203 (36.5%) were women.
Age ranged from 3 to 91 years (mean age, 56.5; median, 59). Follow-up
data varied from a minimum of 6 to a maximum of 605 months (mean, 50.8;
median, 38). Primary skin involvement was defined as the presence of
cutaneous lymphoma without nodal or visceral involvement after complete
staging procedures. Staging procedures were performed with standard
methods available at time of first diagnosis, including, when
applicable, physical examination, blood cell count, chest radiograph,
thoracic computed tomographic scan, abdominal ultrasound sonography,
abdominal computed tomographic scan, sonography of superficial lymph
nodes, positron electron tomography, and bone marrow biopsy. In each
case, the original diagnosis was revised by at least 2 dermatopathologists (L.C., H.K.) based on clinicopathologic criteria.
Patients with so-called "small plaque parapsoriasis" were not
included in this study.
Clinical and follow-up data
All patients were treated with one or more treatment modalities
including surgical excision of the lesions, local radiotherapy, UV-radiation therapy, psoralen-UV-A (PUVA) therapy,
retinoid-PUVA therapy, extracorporal photopheresis, interferon
Histology, immunohistology, molecular
biology
Immunophenotyping was performed on formalin-fixed, paraffin-embedded tissue sections using a 3-step immunoperoxidase technique as described previously,11 with a standard panel of primary antibodies. In all cases where a paraffin block could be retrieved, the analysis of the T-cell receptor (TCR) and immunoglobulin heavy chain (IgH/JH) genes rearrangement were performed using a standard polymerase chain reaction (PCR) technique12,13 with minor modifications as published previously.14 Only cases with clear-cut clinicopathologic and molecular features were included in the study. In particular, the presence of a monoclonal T- or B-cell population in patients presenting with lesions otherwise nondiagnostic on clinicopathologic grounds was not considered sufficient for a diagnosis of T- or B-cell lymphoma, respectively. Statistical analysis End point was the death of the patient, either disease-related or nonspecific. For surviving patients, the study end point was December 31, 1999 or the last available follow-up prior to this date.Statistical analyses were performed using the SPSS/PC statistical
software package (SPSS, Chicago, IL). Survival curves were calculated
using the life table method of Kaplan and Meier. Univariate disease-free interval analysis was calculated using Kaplan-Meier tables
and the log-rank test. P
Of the total group 409 patients (74%) had a cutaneous T-cell
lymphoma (CTCL), and 147 (26%) had a cutaneous B-cell lymphoma (CBCL).
Classification of cutaneous lymphoma, sex, median age, median
follow-up, and estimated 5-year survival are summarized in Table
1. Cases were primarily classified
according to categories listed in the EORTC classification, when
possible. Diagnoses and classification in our patients and comparison
to corresponding categories in the EORTC and the proposed WHO
classifications are summarized in Figure
1.
CTCLs Mycosis fungoides. 281 patients (M:F = 2.02:1). Age range: 9-88 years (mean, 58.1; median, 61). Follow-up: range, 6-605 months (mean, 64; median, 38). Estimated 5-year survival: 89%. EORTC classification: mycosis fungoides. WHO classification: mycosis fungoides/Sezary syndrome. Mycosis fungoides-associated follicular mucinosis. 25 patients (M:F = 4:1). Age range: 33-74 years (mean, 52.3; median, 51). Follow-up: range, 6-262 months (mean, 78.3; median, 51). Estimated 5-year survival: 93%. EORTC classification: mycosis fungoides-associated follicular mucinosis. WHO classification: mycosis fungoides/Sezary syndrome. Pagetoid reticulosis. 1 male patient. Age: 68 years; he developed generalized skin disease 60 months after first diagnosis. EORTC classification: pagetoid reticulosis. WHO classification: mycosis fungoides/Sezary syndrome. Lymphomatoid papulosis. 43 patients (M:F = 1.38:1). Age range: 4-86 years (mean, 44.4; median, 47). Follow-up: range, 6-366 months (mean, 67.7; median, 48). Estimated 5-year survival: 100%. EORTC classification: lymphomatoid papulosis. WHO classification: anaplastic large cell lymphoma, T/null cell, primary cutaneous type. CD30+ cutaneous large T-cell lymphoma. 18 patients (M:F = 3.5:1). Age range: 3-70 years (mean, 50.9; median, 57). Follow-up: range, 6-201 months (mean, 51.4; median, 30). Estimated 5-year survival: 100%. EORTC classification: CD30+ cutaneous large T-cell lymphoma. WHO classification: anaplastic large cell lymphoma, T/null cell, primary cutaneous type. Sezary syndrome. 22 patients (M:F = 4.5:1). Age range: 32-91 years (mean, 65.1; median, 66.5). Follow-up: range, 7-115 months (mean, 39.6; median, 28). Estimated 5-year survival: 33%. EORTC classification: Sezary syndrome. WHO classification: mycosis fungoides/Sezary syndrome. CD30 Subcutaneous "panniculitislike" T-cell lymphoma. 3 patients (M:F = 0.5:1). Age range: 29-48 years (mean, 38.7; median, 39). Follow-up: range: 44-75 months (mean, 57.7; median, 54). Estimated 5-year survival: 100%. EORTC classification: subcutaneous "panniculitislike" T-cell lymphoma (provisional entity). WHO classification: subcutaneous "panniculitislike" T-cell lymphoma. Pleomorphic small/medium-sized cutaneous T-cell lymphoma. 7 patients (M:F = 0.75:1). Age range: 53-80 years (mean, 65.4; median, 65). Follow-up: range, 7-227 months (mean, 83.1; median, 41). Estimated 5-year survival: 80%. EORTC classification: pleomorphic small/medium-sized cutaneous T-cell lymphoma (provisional entity). WHO classification: peripheral T-cell lymphoma, not otherwise characterized. Primary cutaneous natural killer cell lymphoma.
3 patients (M:F = 2:1). Age range: 31-66 years (mean, 53.3; median,
63). Follow-up: range, 30-50 months (mean, 37; median, 31). Estimated
5-year survival: 0%. EORTC classification: CD30 Primary cutaneous CD8+ epidermotropic cytotoxic T-cell
lymphoma.
4 patients (M:F = 3:1). Age range: 48-65 years (mean, 59; median,
61.5). Follow-up: range, 7-36 months (mean, 26; median, 30.5).
Estimated 5-year survival: 0%. EORTC classification:
CD30 CBCLs Primary cutaneous follicle center cell lymphoma. 60 patients (M:F = 0.76:1). Age range: 20-89 years (mean, 58.1; median, 58.5). Follow-up: range, 6-313 months (mean, 67.8; median, 41.5). Estimated 5-year survival: 94%. Forty-five patients presented lesions with a diffuse pattern of growth, and 15 with a follicular pattern. EORTC classification: primary cutaneous follicle center cell lymphoma (PCFCCL). WHO classification: follicular lymphoma; diffuse large B-cell lymphoma. Primary cutaneous immunocytoma/marginal zone B-cell lymphoma. 62 patients (M:F = 1.69:1). Age range: 17-86 years (mean, 51.3; median, 55.5). Follow-up: range, 7-292 months (mean, 67.7; median, 48). Estimated 5-year survival: 98%. EORTC classification: primary cutaneous immunocytoma (marginal zone B-cell lymphoma). WHO classification: extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue [MALT]-type lymphoma). Large B-cell lymphoma of the leg. 23 patients (M:F = 0.76:1). Age range: 43-86 years (mean, 70.6; median, 72). Follow-up: range, 8-168 months (mean, 32; median, 13). Estimated 5-year survival: 58%. EORTC classification: primary cutaneous large B-cell lymphoma of the leg. WHO classification: diffuse large B-cell lymphoma. Plasmacytoma. 2 men aged 50 and 55 years (mean and median, 52.5). Follow-up: range, 12-30 months (mean and median, 21). One patient had skin disease after a follow-up of 12 months; the second had systemic spread after a follow-up of 30 months. EORTC classification: primary cutaneous plasmacytoma (provisional entity). WHO classification: extramedullary plasmacytoma.
The classification of PCLs is the subject of ongoing debates.4,16-18 At present, 2 main classification schemes are used. The first one was proposed by the EORTC in 1997,3 and the second is based on the classification of hematologic malignancies proposed by WHO, which is an update of the REAL classification.6 Overall analysis of our data shows that patients with PCL are better classified according to the EORTC classification than to the scheme proposed by WHO. Figure 1 summarizes the entities that could be observed in our group of patients and corresponding EORTC and WHO categories. The need for a special classification of lymphomas arising primary in the skin is supported also by the notion of the existence of special adhesion receptors ("homing receptors") regulating the traffic of normal and neoplastic lymphocytes, thus underlying the concept of "organ-bound" lymphomas.19 Although in the EORTC classification of PCL was defined as presence of disease limited to the skin for at least 6 months after complete staging procedures, based on 2 main reasons we defined it as negative staging at presentation. First, aggressive lymphomas that arise within the skin may show dissemination before a period of 6 months; second and most important, patients need to be treated at presentation, thus a clear-cut diagnosis must be established immediately, not 6 months afterward. Comparison of data for specific diagnostic categories demonstrated nearly complete concordance of our results with those of the EORTC study for most of the indolent CTCLs.3 A major difference, however, was found concerning mycosis fungoides-associated follicular mucinosis. In fact, we could observe no statistically significant difference in survival among patients with "classic" mycosis fungoides and those with mycosis fungoides-associated follicular mucinosis (log-rank; P = .22), whereas in the EORTC study the estimated 5-year survival of mycosis fungoides-associated follicular mucinosis was 70%, as compared to 87% for patients with "classic" mycosis fungoides.3 Thus, our data do not support distinction of this variant of mycosis fungoides into a separate category. It is also interesting that in our study, one patient with localized pagetoid reticulosis developed generalized skin lesions 5 years after the onset of the disease. Localized pagetoid reticulosis with subsequent onset of generalized lesions has been described in the past,20 and might show a prognosis similar to that of mycosis fungoides,21 underlying the need for long-term follow-up for these patients. A difference in survival data between our study and that of the EORTC was found for patients with Sezary syndrome. Our estimated 5-year-survival rate of 33% is similar to those reported by Bernengo et al22 and by Marti et al.23 In contrast, the estimated 5-year survival reported by the EORTC group was only 11%.3 This discrepancy is probably due to the use of different diagnostic criteria, resulting in selection of different groups of patients.24,25 It should be underlined, however, that the prognosis of patients with Sezary syndrome is much worse than that of patients with mycosis fungoides, and that treatment modalities are different, supporting the inclusion of these patients into separate categories, as in the EORTC classification, and in contrast to the WHO classification. Interestingly, an estimated 5-year survival of 100% could be found for our patients with subcutaneous "panniculitislike" T-cell lymphoma, in contrast to the data reported in the EORTC classification.3 It should be underlined, however, that we observed only 3 patients with this entity and that in our cases, reclassification of older biopsies, reported originally as "lupus panniculitis" or "nonspecific lobular panniculitis," resulted in considerably longer survival rates. In fact, molecular analyses performed retrospectively demonstrated the presence of the same monoclonal population of T lymphocytes in biopsies previously considered to be nondiagnostic. It seems likely that subcutaneous "panniculitislike" T-cell lymphoma is underdiagnosed, and that many patients indeed experience a chronic course of disease with prolonged survival.26,27 A small percentage of CTCLs (16 cases) in our study could be classified
into 4 diagnostic categories present only in part in the EORTC and WHO
schemes (pleomorphic small/medium-sized CTCL, CD30 There was almost complete concordance between our data and those reported in the EORTC study concerning prognostic features for all 3 major categories of CBCL considered in the EORTC classification. PCFCCLs are reported as the most common type of primary CBCL in the EORTC classification,3 whereas in our group of patients primary cutaneous immunocytoma/marginal zone B-cell lymphoma was slightly more represented. These data most likely reflect regional variation in the incidence of different lymphoma subtypes. Concerning PCFCCL, one main problem is that many cases classified in this group in the EORTC classification would be included among the diffuse large B-cell lymphomas in the WHO classification.6 In fact, the majority of cutaneous cases are characterized by a diffuse pattern of growth with predominance of medium to large centrocytes and centroblasts, and a follicular pattern is seen only in a minority of cases.30,31 However, patients with PCFCCL show an indolent course, irrespective of the histopathologic and cytomorphologic features of the infiltrate, and aggressive therapy is not justified. Primary cutaneous immunocytoma/marginal zone B-cell lymphoma would be classified among the extranodal marginal zone lymphoma of the MALT type in the WHO classification.6 However, this group includes B-cell lymphomas arising in such disparate organs as the stomach, thyroid, and salivary glands among others. Many of these lymphomas arise in the setting of chronic antigenic stimulation due to microbacterial antigens (ie, Helicobacter pylori) or autoimmune diseases.32,33 Although the role of Borrelia burgdorferi has been suggested for a small proportion of CBCLs,34 in most cases neither bacterial nor autoimmune diseases can be observed. Moreover, treatment modalities are different from those applied for the extracutaneous MALT-type lymphomas, thus suggesting that they should be considered as a separate entity. However, the term "immunocytoma" for cutaneous cases may be the source of confusion, because in the proposed WHO classification it is used for a distinct group of systemic lymphomas often associated with Waldenstrom macroglobulinemia.6 Another controversy concerns the distinction of primary cutaneous marginal zone lymphoma from immunocytoma. Although we believe that there are clinical and histopathologic differences between the 2 groups,14 similarities in prognosis and treatment suggested the EORTC to classify these patients in one single category.3 In the proposed WHO classification cases of extramedullary plasmacytoma are mentioned only as variants of plasmacytomas, without reference to the site of onset,6 whereas in the EORTC classification plasmacytoma is included only as a provisional entity. Based on data from the literature and from our 2 patients, the prognosis of primary cutaneous plasmacytoma seems to be good,35-37 justifying its inclusion into the group of indolent CBCLs as a distinct clinicopathologic entity. In our study, we could find similar survival data for patients with primary cutaneous large B-cell lymphoma of the leg, when compared to those published in the EORTC study.3 There has been much debate concerning the terminology of this type of cutaneous lymphoma, especially because a distinct, albeit small proportion of the cases arises at body sites other than the legs.38-41 However, primary cutaneous large B-cell lymphoma of the leg represents a category that should be clearly separated from the "diffuse" type of PCFCCL, because cytomorphology and prognosis are clearly different. Moreover, most cases do indeed arise on the legs. The term "large B-cell lymphoma of the leg" underlines one distinctive clinical feature of this cutaneous lymphoma, and can be paralleled to terminology of other lymphomas currently classified according to the site of onset (ie, nasal lymphoma, hepatosplenic lymphoma, etc). In conclusion, our study confirmed that most primary CTCLs and CBCLs can be classified according to the entities listed in the EORTC classification. It may be necessary to perform small amendments to this classification to take into account recently described entities and to unify some of the diagnostic categories.
Submitted April 11, 2001; accepted August 8, 2001.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Lorenzo Cerroni, Dept of Dermatology, University of Graz, Auenbruggerplatz 8, A-8036 Graz, Austria; e-mail: lorenzo.cerroni{at}kfunigraz.ac.at.
1. Stansfeld AG, Diebold J, Kapanci Y, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292-293[Medline] [Order article via Infotrieve].
2.
Harris NL, Jaffe ES, Stein H.
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
Blood.
1994;84:1361-1392
3.
Willemze R, Kerl H, Sterry W, et al.
EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European Organization for Research and Treatment of Cancer.
Blood.
1997;90:354-371 4. Sander CA, Kind P, Kaudewitz P, Raffeld M, Jaffe ES. The revised European-American classification of lymphoid neoplasms (REAL): a new perspective for the classification of cutaneous lymphomas. J Cutan Pathol. 1997;24:329-341[CrossRef][Medline] [Order article via Infotrieve]. 5. Sander CA, Flaig MJ, Kaudewitz P, Jaffe ES. The revised European-American Classification of Lymphoid Neoplasm (REAL): a preferred approach for the classification of cutaneous lymphomas. Am J Dermatopathol. 1999;21:274-278[CrossRef][Medline] [Order article via Infotrieve] 6. Harris NL, Jaffe ES, Diebold J, et al. Conference report. The World Health Organization classification of neoplastic disease of the haematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee, Airlie House, Virginia, November 1997. Histopathology. 2000;36:69-87[CrossRef][Medline] [Order article via Infotrieve].
7.
Grange F, Hedelin G, Joly P, et al.
Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sezary syndrome.
Blood.
1999;93:3637-3642 8. Willemze R, Meijer CJLM, Sentis HJ, et al. Primary cutaneous large cell lymphomas of follicular center cell origin. A clinical follow-up study of nineteen patients. J Am Acad Dermatol. 1987;16:518-526[Medline] [Order article via Infotrieve]. 9. Beljaards RC, Meijer CJLM, van der Putte SCJ, et al. Primary cutaneous T-cell lymphoma: clinicopathological features and prognosis parameters of 35 cases other than mycosis fungoides and CD-30-positive large cell lymphoma. J Pathol. 1994;172:53-60[CrossRef][Medline] [Order article via Infotrieve]. 10. Pimpinelli N, Santucci M, Bosia A. Primary cutaneous follicular centre cell-lymphoma: a lymphoproliferative disease with favourable prognosis. Clin Exp Dermatol. 1989;14:12-19[CrossRef][Medline] [Order article via Infotrieve]. 11. Cerroni L, Smolle J, Soyer HP, Martinez Aparicio A, Kerl H. Immunophenotyping of cutaneous lymphoid infiltrates in frozen and paraffin-embedded tissue sections. A comparative study. J Am Acad Dermatol. 1990;22:405-413[Medline] [Order article via Infotrieve].
12.
McCarthy KP, Sloane JP, Kabarowski JHS, Matutes E, Wiedemann LM.
A simplified method of detection of clonal rearrangements of the T-cell receptor-
13.
Wan JH, Trainor KJ, Brisco MJ, Morley AA.
Monoclonality in B cell lymphoma detected in paraffin wax embedded sections using the polymerase chain reaction.
J Clin Pathol.
1990;43:888-890 14. Cerroni L, Signoretti S, Höfler G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol. 1997;21:1307-1315[CrossRef][Medline] [Order article via Infotrieve]. 15. Sachs I. Angewandte Statistik. Anwendung Statistischer Methoden. Berlin: Springer; 1984:183-186. 16. Jaffe ES, Sander CA, Flaig MJ. Cutaneous lymphomas: a proposal for a unified approach to classification using the REAL/WHO classification. Ann Oncol (suppl). 2000;S17-S21. 17. Kerl H, Cerroni L. Controversies in cutaneous lymphomas. Semin Cutan Med Surg. 2000;19:157-160[Medline] [Order article via Infotrieve]. 18. Willemze R, Meijer CJLM. EORTC classification for primary cutaneous lymphomas: the best guide to good clinical management. Am J Dermatopathol. 1999;21:265-273[CrossRef][Medline] [Order article via Infotrieve].
19.
Drillenburg P, Pals ST.
Cell adhesion receptors in lymphoma dissemination.
Blood.
2000;95:1900-1910 20. Yagi H, Hagiwara T, Shirahama S, Tokura Y, Takigawa M. Disseminated pagetoid reticulosis: need for long term follow-up. J Am Acad Dermatol. 1994;30:345-349[Medline] [Order article via Infotrieve]. 21. Haghighi B, Smoller BR, LeBoit PE, Warnke RA, Sander CA, Kohler S. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol. 2000;13:502-510[CrossRef][Medline] [Order article via Infotrieve].
22.
Bernengo MG, Quaglino P, Novelli M, et al.
Prognostic factors in Sezary syndrome: a multivariate analysis of clinical, haematological and immunological features.
Ann Oncol.
1998;9:857-863 23. Marti RM, Estrach T, Gonzalez J, et al. Sezary syndrome (SS): a descriptive study of 29 cases [abstract]. J Invest Dermatol. 1997;109:494. 24. Willemze R, Beljaards RC, Meijer CJLM. Classification of primary cutaneous T-cell lymphomas. Histopathology. 1994;24:405-415[Medline] [Order article via Infotrieve]. 25. Russel-Jones R, Whittaker S. Sezary syndrome: diagnostic criteria and therapeutic options. Semin Cutan Med Surg. 2000;19:100-108[Medline] [Order article via Infotrieve].
26.
Winkelmann RK, Bowie EJW.
Hemophagic diathesis associated with benign histiocytic, cytophagic panniculitis and systemic histiocytosis.
Arch Intern Med.
1980;140:1460-1463
27.
Perniciaro C, Zalla MJ, White JW, Menke DM.
Subcutaneous T-cell lymphoma: report of two additional cases and further observations.
Arch Dermatol.
1993;129:1171-1176
28.
Berti E, Tomasini D, Vermeer MH, Meijer CJLM, Alessi E, Willemze R.
Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
Am J Pathol.
1999;155:483-492 29. Cerroni L, Kerl H, Gatter K. Natural killer cell lymphoma An Illustrated Guide to Skin Lymphoma. Oxford United Kingdom: Blackwell Science; 1998:55-58.
30.
Cerroni L, Arzberger E, Pütz B, et al.
Primary cutaneous follicle center cell lymphoma with follicular growth pattern.
Blood.
2000;95:3922-3928
31.
Cerroni L, Kerl H.
Primary cutaneous follicular lymphoma.
Arch Dermatol.
2001;137:489-490 32. Isaacson PG, Norton AJ. Cutaneous lymphomas Extranodal Lymphomas. Edinburgh United Kingdom: Churchill Livingstone; 1994:5-14. 33. Hyjek E, Isaacson PG. Primary B-cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis. Hum Pathol. 1988;19:1315-1326[Medline] [Order article via Infotrieve]. 34. Cerroni L, Zöchling N, Pütz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997;24:457-461[CrossRef][Medline] [Order article via Infotrieve]. 35. Torne R, Su WPD, Winkelmann RK, Smolle J, Kerl H. Clinicopathologic study of cutaneous plasmacytoma. Int J Dermatol. 1990;29:562-566[Medline] [Order article via Infotrieve]. 36. Tuting T, Bork K. Primary plasmacytoma of the skin. J Am Acad Dermatol. 1996;34:386-390[Medline] [Order article via Infotrieve].
37.
Galieni P, Cavo M, Pulsoni A, et al.
Clinical outcome of extramedullary plasmacytoma.
Haematologica.
2000;85:47-51 38. Russell-Jones R. Primary cutaneous B-cell lymphoma: how useful is the new European Organization for Research and Treatment of Cancer (EORTC) classification? Br J Dermatol. 1998;139:945-949[CrossRef][Medline] [Order article via Infotrieve]. 39. Slater DN. Primary cutaneous B-cell lymphoma: how useful is the new European Organization for Research and Treatment of Cancer classification? Br J Dermatol. 1999;141:352-353[CrossRef][Medline] [Order article via Infotrieve]. 40. Sterry W. Classification of primary cutaneous B-cell lymphomas. Br J Dermatol. 1999;141:353-354[CrossRef][Medline] [Order article via Infotrieve]. 41. Norton AJ. Classification of cutaneous lymphoma. A critical appraisal of recent proposals. Am J Dermatopathol. 1999;21:279-287[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  A. Garcia-Herrera, L. Colomo, M. Camos, J. Carreras, O. Balague, A. Martinez, A. Lopez-Guillermo, T. Estrach, and E. Campo Primary Cutaneous Small/Medium CD4+ T-Cell Lymphomas: A Heterogeneous Group of Tumors With Different Clinicopathologic Features and Outcome J. Clin. Oncol., July 10, 2008; 26(20): 3364 - 3371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grange, M. Beylot-Barry, P. Courville, E. Maubec, M. Bagot, B. Vergier, P. Souteyrand, L. Machet, S. Dalac, E. Esteve, et al. Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Clinicopathologic Features and Prognostic Analysis in 60 Cases Arch Dermatol, September 1, 2007; 143(9): 1144 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Senff, J. J. Hoefnagel, P. M. Jansen, M. H. Vermeer, J. van Baarlen, W. A. Blokx, M. R. Canninga-van Dijk, M.-L. Geerts, K. M. Hebeda, P. M. Kluin, et al. Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO-EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic Markers J. Clin. Oncol., April 20, 2007; 25(12): 1581 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Cerroni Lymphoproliferative lesions of the skin. J. Clin. Pathol., August 1, 2006; 59(8): 813 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kodama, C. Massone, A. Chott, D. Metze, H. Kerl, and L. Cerroni Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients Blood, October 1, 2005; 106(7): 2491 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Hoefnagel, M. H. Vermeer, P. M. Jansen, F. Heule, P. C. van Voorst Vader, C. J. G. Sanders, M. J. P. Gerritsen, M. L. Geerts, C. J. L. M. Meijer, E. M. Noordijk, et al. Primary Cutaneous Marginal Zone B-Cell Lymphoma: Clinical and Therapeutic Features in 50 Cases Arch Dermatol, September 1, 2005; 141(9): 1139 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Smith, G. L. Smith, D. L. Cooper, and L. D. Wilson The Cutaneous B-Cell Lymphoma Prognostic Index: A Novel Prognostic Index Derived From a Population-Based Registry J. Clin. Oncol., May 20, 2005; 23(15): 3390 - 3395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Willemze, E. S. Jaffe, G. Burg, L. Cerroni, E. Berti, S. H. Swerdlow, E. Ralfkiaer, S. Chimenti, J. L. Diaz-Perez, L. M. Duncan, et al. WHO-EORTC classification for cutaneous lymphomas Blood, May 15, 2005; 105(10): 3768 - 3785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Grange, T. Petrella, M. Beylot-Barry, P. Joly, M. D'Incan, M. Delaunay, L. Machet, M.-F. Avril, S. Dalac, P. Bernard, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas Blood, May 15, 2004; 103(10): 3662 - 3668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Smith, E. J. Glusac, J. M. McNiff, G. L. Smith, P. W. Heald, D. L. Cooper, and L. D. Wilson Primary Cutaneous B-Cell Lymphoma Treated With Radiotherapy: A Comparison of the European Organization for Research and Treatment of Cancer and the WHO Classification Systems J. Clin. Oncol., February 15, 2004; 22(4): 634 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Bekkenk, M. H. Vermeer, P. M. Jansen, A. M. W. van Marion, M. R. Canninga-van Dijk, P. M. Kluin, M.-L. Geerts, C. J. L. M. Meijer, and R. Willemze Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients Blood, September 15, 2003; 102(6): 2213 - 2219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Connors, E. D. Hsi, and F. M. Foss Lymphoma of the Skin Hematology, January 1, 2002; 2002(1): 263 - 282. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
,
alive and well; A+(s), alive with skin disease alone; A+(v), alive with
systemic spread; D+, dead of disease; D
2a, combination of one or more of the aforementioned therapies, and
mono- or polychemotherapy. Many patients received different therapies
at different times. The effects of therapy were not included in our study.
.05 was considered to indicate statistical significance.
cutaneous large T-cell lymphoma.
One male and one female patient. Age range: 34-76 years (mean,
55; median, 55). Follow-up: range, 7-11 months (mean, 9; median, 9).
Both patients had skin disease alone after the follow-up of 7 and 11 months, respectively. EORTC classification: CD30
chain gene.
Diagn Mol Pathol.
1992;1:173-179